Expert NetworkExpert InterviewNVO

Slingshot members are talking to an expert! The topic is:

Discussing the potential of INV-202 (Monlunabant), a CB1 antagonist currently in development by Novo Nordisk for weight loss

Executed on:Aug 20, 2024 10:30 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: University Clinic Salzburg
  • Professor of Pediatrics at Paracelsus Medical School in Salzburg, Austria
  • Manages 500+ child/adolescent patients with Obesity
  • Research and clinical interest in metabolic comorbidities including glucose and fat metabolism

Interview Goal

Discuss validity of targeting CB1 receptor for obesity

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.